Resminostat - CISMeF

Preferred Label : Resminostat;

NCIt definition : An orally bioavailable inhibitor of histone deacetylases (HDACs) with potential antineoplastic activity. Resminostat binds to and inhibits HDACs leading to an accumulation of highly acetylated histones. This may result in an induction of chromatin remodeling, inhibition of the transcription of tumor suppressor genes, inhibition of tumor cell division and the induction of tumor cell apoptosis. HDACs, upregulated in many tumor types, are a class of enzymes that deacetylate chromatin histone proteins.;

UNII : 1578EUB98L;

InChIKey : FECGNJPYVFEKOD-VMPITWQZSA-N;

CAS number : 864814-88-0;

Molecule name : 4SC-201;

Chemical formula : C16H19N3O4S;

Détails

Origin ID

C84856;

UMLS CUI

C2935131;

Currated CISMeF NLP mapping
- Resminostat [SMS substance]
- resminostat [MeSH concept]
- resminostat [MeSH Supplementary Concept]
Semantic type(s)
- Organic Chemical [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- resminostat [MeSH Supplementary Concept]
- resminostat [MeSH concept]
concept_is_in_subset
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- GDC Value Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]

Position du mot-clé dans l'(les) arborescence(s) :

Vous pouvez consulter :

recommendations
documents concerning education
documents for patients